Skip to content

Science

Graphic showing NTS-521 as a pro-drug that converts to the active drug NTS-105, which crosses the BBB through a multi-targeted mechanism.

Water-Soluble Prodrugs of the Neuroactive Steroid, NTS-105

Our compounds rapidly convert to NTS-105, a neuroactive steroid (active molecule) in plasma following parenteral administration of the prodrug. NTS-105 readily crosses the blood brain barrier, reaches pharmacologic concentrations in the brain and plasma, and has multi-targeted mechanisms of action.

Graphic explaining NTS-105’s mechanism of action across androgen, progesterone, and mineralocorticoid receptors.

NTS has performed rigorous preclinical evaluation of NTS-105 in multiple independent laboratories utilizing multiple models of brain injury, including ischemic and mechanical injuries.

In a rat model of stroke that mimics the emboli that often cause stroke in humans, NTS-105 has shown the ability to reduce the volume of infarction in the brain in a dose-dependent manner.

Figure showing lower infarct volumes across increasing NTS-105 doses with brain images highlighting infarcted areas in red.

In the same animals as the study above (infarct volumes), NTS-105 treatment led to faster and more complete recovery in the 4 weeks following stroke.

Line chart showing neurologic severity scores improving over time after stroke across vehicle and increasing NTS-105 dose groups.

Two dose-response charts showing changes in hippocampal edema and cylinder task performance across increasing treatment doses.

In a model of traumatic brain injury, Lateral Fluid Percussion (LFP), treatment with NTS-105 reduced edema in a dose-dependent manner. Edema (brain swelling) is a primary mechanism by which mechanical injuries cause widespread damage within the brain.

We also found a concomitant increase in the animals’ ability to use their forelimbs after injury, as measured by the Cylinder Task, a well-accepted model of forelimb recovery. Zhang et al. Stroke 2022

NTS is taking a rational approach toward clinical study design. The information we can glean from preclinical studies, human pharmacokinetics, and molecular studies of how NTS-105 interacts with receptors allows us to predict proper human dose levels with a high degree of precision.

Top